TrialScientific reports2023

Randomized phase II study of preoperative afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of activity.

Grégoire Marret et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.